GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of GoodRx (NASDAQ:GDRX) from a hold rating to a buy rating in a research note released on Saturday.

Several other brokerages have also commented on GDRX. Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. The Goldman Sachs Group reissued a “neutral” rating and set a $4.00 target price on shares of GoodRx in a research report on Friday, August 7th. TD Cowen raised their price target on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday. Citigroup lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price objective on GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, GoodRx currently has an average rating of “Hold” and an average target price of $4.14.

GoodRx Stock Up 0.3%

Shares of NASDAQ:GDRX opened at $3.73 on Friday. The company has a market capitalization of $1.28 billion, a PE ratio of 93.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The business has a fifty day moving average price of $3.03 and a two-hundred day moving average price of $2.59. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted $0.09 EPS. Analysts forecast that GoodRx will post 0.16 earnings per share for the current year.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its holdings in shares of GoodRx by 43.6% in the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after acquiring an additional 5,201 shares during the period. Brevan Howard Capital Management LP raised its stake in shares of GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after purchasing an additional 6,842 shares during the period. Hirtle Callaghan & Co LLC lifted its holdings in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock worth $49,000 after purchasing an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after purchasing an additional 7,580 shares in the last quarter. Finally, Quarry LP bought a new position in GoodRx in the 3rd quarter worth about $33,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.